Poster Session 3-11 CML: Clinical (2)

[PS3-11-4] Switch from dasatinib to nilotinib in combination with interferon-α for CML with T315I-mutation

Masahiko Chiwata¹, Hidehiro Itonaga², Machiko Fujioka^1,2, Jun Nakashima¹, Mori Sayaka³, Daisuke Sasaki³, Emi Matsuo⁴, Takeharu Kato¹, Shinichiro Yoshida¹, Hiroo Hasegawa³, Tomoko Hata², Katsunori Yanagihara³, Yasushi Miyazaki² (1.Hematology, National Hospital Organization Nagasaki Medical Center, Ohmura, Japan, 2.Hematology, Nagasaki University Hospital, Nagasaki, Japan., 3.Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan., 4.Hematology, Isahaya General Hospital, Isahaya, Japan.)